Drug intelligence / Profile preview

saredutant + escitalopram

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

This is a **combination drug** consisting of **saredutant** and **escitalopram**, studied for the treatment of major depressive disorder. Saredutant is a neurokinin-2 (NK2) receptor antagonist, while escitalopram is a selective serotonin reuptake inhibitor (SSRI). Escitalopram modulates serotonergic neurotransmission by inhibiting serotonin reuptake, while saredutant inhibits the action of substance P by blocking NK2 receptors, potentially reducing depressive and anxiety symptoms. The combination has reached at least Phase 3 clinical trials for depression. No unique brand name exists for this combination.

Targets

SERT (Sodium-dependent serotonin transporter)TACR2 (Neurokinin-2 Receptor)

Beyond the preview

Go deeper on saredutant + escitalopram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on saredutant + escitalopram.

Explore the full profile